Drugs / THN391
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06814730 | Jul 2025 → Mar 2027 expected | — | Therini Bio, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06701721 | Dec 2024 → Mar 2027 expected | diabetic macular edema | Therini Bio Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-29 | Therini Bio, Inc. | Results Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases therinibio.com ↗
Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced positive results from a Phase 1a trial assessing its lead candidate, THN391, in healthy volunteers for the treatment of neurodegenerative diseases. |
| 2024-05-08 | Therini Bio, Inc. | Results Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases therinibio.com ↗
In preclinical models of macular degeneration and diabetic retinopathy, THN391 and its analogs demonstrated effectiveness in protecting against vascular and neuronal degeneration. |
| 2023-10-24 | Therini Bio, Inc. | Results Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia therinibio.com ↗
THN391 was found to be safe and well-tolerated |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Therini Bio, Inc. | Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema therinibio.com ↗ |
| 2025-07-29 | Therini Bio, Inc. | Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease therinibio.com ↗ |
| 2025-04-29 | Therini Bio, Inc. | Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases therinibio.com ↗ |
| 2024-05-08 | Therini Bio, Inc. | Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases therinibio.com ↗ |
| 2023-10-24 | Therini Bio, Inc. | Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia therinibio.com ↗ |
| 2023-05-15 | Therini Bio, Inc. | Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease therinibio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THN391 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06701721 ↗ |
| Route | Intravitreal | “Intravitreal THN391” NCT06701721 ↗ |